DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to $46

BMO Capital maintains Horizon Therapeutics (NASDAQ:HZNP) with a Outperform and raises the price target from $40 to $46.

Benzinga · 01/22/2020 15:21

BMO Capital maintains Horizon Therapeutics (NASDAQ:HZNP) with a Outperform and raises the price target from $40 to $46.